Welcome Mauricio to the Pulse Economics team
We’re excited to welcome Mauricio Andrade to the Pulse Economics team as a senior consultant! To celebrate, we recently held a welcome lunch at Mordeo Italian restaurant in Sydney with…
Our Blog
5 Common Mistakes Sponsors Make in MSAC Submissions for Diagnostic and Investigative Technologies
For sponsors seeking public reimbursement in Australia, submissions for diagnostic and investigative technologies present a fundamentally different challenge to therapeutic services. Under the Medical Services Advisory Committee (MSAC) framework, diagnostic…
Market Access Discussion Forum: PBAC IO Broad Listing Case Study
Attend our Market Access Discussion Forum tailored for professionals in the pharmaceutical industry! This event provides a unique platform to network with fellow experts and engage in in-depth discussions on…
Pulse Economics joins national Advanced Therapies Advisory Group
Pulse Economics is pleased to share that Oona Reardon, Managing Director, has been appointed as a member of the newly established Medicines Australia and AusBiotech Advanced Therapies Advisory Group. The Advisory Group brings together industry, policy and…
Top 8 things medical device companies need to know after the Prescribed List reforms
For medical device companies seeking reimbursement in the Australian private hospital system, inclusion on the Prescribed List (PL) remains critical. What has changed is that the Prescribed List is no…
Lived experience and diabetes technology
The Diabetes Australia Grand Innovation Challenge launches today and it’s tackling something the sector desperately needs. Australia is in short supply of early-stage funding for medtech and digital health solutions…
MFN 2.0: How the US GENEROUS model could quietly reshape global pricing and put Australia on the back foot
On 6 November 2025, the US Centers for Medicare & Medicaid Services (CMS) announced the GENEROUS (GENErating cost Reductions fOr US Medicaid) Model, a 5-year voluntary pilot starting in 2026.…
What pharma companies need to know about the new PBS Notice of Intent requirements
The Department of Health, Disability and Ageing has announced changes to their PBS Notice of Intent (NOI) process that will impact your market access timeline and preparation strategy for submissions…
Market Access Forum for Pharma Industry Professionals
Attend our Market Access Forum tailored for professionals in the pharmaceutical industry! This event provides a unique platform to network with fellow experts and engage in in-depth discussions on various…
We’ve joined the National AI Centre’s AI Directory
Exciting news! Pulse Economics is proud to be listed on the National AI Centre’s AI Directory, a platform showcasing Australia’s AI capabilities across industries and technologies. As commercialisation strategy experts,…
Future proofing HTA: critical conversations for Australian healthcare
Key challenges and opportunities shaping health technology assessment Next Tuesday’s ISPOR workshop brings together Australia’s leading HTA stakeholders: PBAC members, HTA Review Implementation Advisory Committee representatives, academics, and industry experts…
The digital health market access challenge in Australia
What we’re seeing We’ve been working with some remarkable Australian digital health companies lately. These are teams with genuinely impressive clinical evidence and technology that could meaningfully improve patient care.…